FTC Says PBMs Netted Billions with “Substantial” Markups on Specialty Generic Drugs
- January 17, 2025
The three largest pharmacy benefit managers (PBMs)—CVS Health Corp.’s Caremark Rx, Cigna Group’s Express Scripts, and UnitedHealth Group Inc.’s Optum Rx—inflated prices on specialty generic drugs, generating more than $7.3 billion in revenue above their estimated acquisition costs from 2017-2022, according to a Federal Trade Commission’s (FTC) interim staff report issued January 14.
ARTICLE TAGS
You must be logged in to access this content.